https://techpapersworld.com/wp-content/uploads/2022/05/Addex-Announces-Participation-in-the-H.C.-Wainwright-Global-1280x720.jpg

Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 – 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex. The presentation will be available for viewing on-demand by registered participants. Mr. Dyer...